Levitee Labs Inc. announced a new strategic collaboration with the LiveRx Research Group for testing, treating, and curing HCV in Alberta. LiveRx is a project led by Dr. Mark G. Swain, Head of the Division of Gastroenterology and Hepatology at the University of Calgary and funded by The Alberta Innovates Partnership for Research and Innovation in the Health System (PRIHS) funding program. LiveRx is dedicated to addressing inequities in the current specialist referral-based HCV care model. Levitee Labs and LiveRx will work jointly to create an equitable, patient-centric HCV care model that facilitates shifting HCV care from specialist treatment centers in urban centers to easily accessible clinics and pharmacies across the province. As part of the collaboration agreement, Levitee Labs will implement the LiveRx HCV test and treat program at its Levitee Clinics and Levitee Pharmacies across Alberta from January 2022 through January 2024. The following activities will be part of the collaboration with LiveRx: Conducting HCV screening and testing for Levitee Clinics patients. Including patients identified with HCV who are within the Levitee Clinics care program as part of the LiveRx HCV eradication research program. Undertaking HCV treatment for appropriate HCV-infected individuals through a Levitee-linked pharmacy with full support of LiveRx where available. Promoting the LiveRx program at Levitee Clinics and Levitee Pharmacies sites. Communicating regularly with the LiveRx Research Group to assess implementation successes, challenges, and further needs, and make mutually agreed upon changes where appropriate. In Canada, it is estimated that 250,000 Canadians are living with chronic HCV and thousands of new cases are diagnosed each year. 44% of those infected are unaware of their HCV status; symptoms can take two weeks to six months to appear, and most people will not develop symptoms. If left untreated, HCV can progress over time to serious liver damage and is associated with a range of systemic health problems, decreased quality of life, and increased healthcare costs. The North American HCV drug market was valued at USD 3.7 billion as of 2018.